Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU)

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU) / Bumert, B., Hegi, M., Van Den Bent, M., Von Deimling, A., Gorlia, T., Hoang-Xuan, K., Brandes, A., Sargos, P., Taphoorn, M., Vauleon, E., Philips, C., Kros, J., Bady, P., Wick, W., Enting, R., Reni, M., Thiessen, B., Dhermail, F., Bronberg, J., Jacob, J., et al.. - (2026). [Epub ahead of print]